Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Geron Corporation to Contact

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of 
$100,000 Investing in Geron Corporation to Contact the Firm 
NEW YORK, NY -- (Marketwired) -- 03/19/14 --  Faruqi & Faruqi, LLP, a
leading national securities law firm, reminds investors in Geron
Corporation ("Geron" or the "Company") (NASDAQ: GERN) of the May 13,
2014 deadline to seek the role of lead plaintiff in a federal
securities class action lawsuit filed against Geron and certain
A complaint has been filed on behalf of all persons who purchased
Geron securities between June 16, 2013 and March 11, 2014, inclusive
(the "Class Period") in the Northern District of California. 
The complaint alleges that the Company and its executives violated
federal securities laws with respect to its disclosures concerning
its business, operations, and prospects. 
Specifically, the action alleges that throughout the Class Period
defendants made false and/or misleading statements and/or failed to
disclose that: (i) persistent low-grade liver function test (LFT)
abnormalities were observed in the Phase 2 study of imetelstat,
Geron's sole product candidate; and (ii) the potential danger of
chronic injury to the liver existed for patients with long-term
exposure to imetelstat. 
On March 12, 2014, the Company announced that it has received verbal
notice from the FDA that its investigational new drug application for
imetelstat had been place on full clinical hold, which affects all
ongoing company-sponsored clinical trials. 
Following this news, the Company's stock declined $2.71 per share, or
over 61%, to close at $1.69 per share on March 12, 2014. 
Request more information now by clicking here:
www.faruqilaw.com/GERN. There is no cost or obligation to you. 
Take Action 
If you invested in Geron stock or options between June 16, 2013 and
March 11, 2014 and would like to discuss your legal rights, visit
www.faruqilaw.com/GERN. You can also contact us by calling Richard
Gonnello or Francis McConville toll free at 877-247-4292 or at
212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or
fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages
anyone with information regarding Geron's conduct to contact the
firm, including whistleblowers, former employees, shareholders and
Faruqi & Faruqi, LLP is a national law firm which represents
investors and individuals in class action litigation. The firm is
focused on providing exemplary legal services in complex litigation
in the areas of securities, shareholder, antitrust and consumer
litigation, throughout all phases of litigation. The firm has an
experienced trial team which has achieved significant victories on
behalf of the firm's clients. To keep track of the latest securities
litigation news, follow us on Twitter at
www.twitter.com/MergerActivity or on Facebook at
 Attorney Advertising. The law firm
responsible for this advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or predict a
similar outcome with respect to any future matter. We welcome the
opportunity to discuss your particular case. All communications will
be treated in a confidential manner. 
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292
(212) 983-9330 
Press spacebar to pause and continue. Press esc to stop.